Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan.
Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Diabetes Res Clin Pract. 2023 Aug;202:110674. doi: 10.1016/j.diabres.2023.110674. Epub 2023 Apr 21.
To investigate whether any reduction in all-cause mortality and cardiovascular disease morbidity was found over the decade in type 2 diabetes on real-world practice.
A prospective observational study was performed by following two independent cohorts recruited in 2004 (n = 3286, Cohort 1) and 2014 (n = 3919, Cohort 2). The primary outcome was a composite of onset of cardiovascular disease and death. Cox proportional hazards analysis was used to explore any difference between Cohort 2 and Cohort 1 for the composite endpoints and cardiovascular disease after adjustment for covariates and accumulation of five risks (smoking, HbA1c, blood pressure, lipids, and albuminuria) outside target ranges.
During the 8-year follow-up, 391 (11.9%) and 270 (6.9%) primary outcomes, and 270 (8.2%) and 161 (4.1%) cardiovascular diseases occurred in Cohort 1 and Cohort 2, respectively. Cohort 2 (vs. Cohort 1) exhibited a significant risk reduction for composite endpoints (HR 0.73, 95% CI 0.62 to 0.86) and cardiovascular disease (HR 0.64, 95% CI 0.52 to 0.79), and similarly exhibited a significant reduction independent of the accumulation of the five risks.
The significant reduction of Cohort 2 for cardiovascular disease independent of the baseline covariates suggests an integrated effect delivered by the recent treatment advances.
在真实世界的实践中,研究 2 型糖尿病患者在过去十年中是否在全因死亡率和心血管疾病发病率方面有所降低。
通过随访 2004 年(n=3286,队列 1)和 2014 年(n=3919,队列 2)招募的两个独立队列进行前瞻性观察研究。主要结局是心血管疾病和死亡的复合终点。采用 Cox 比例风险分析探讨队列 2 与队列 1 之间在复合终点和心血管疾病方面的差异,调整协变量和五个风险(吸烟、HbA1c、血压、血脂和蛋白尿)超出目标范围的累积后。
在 8 年的随访中,队列 1 中分别有 391(11.9%)和 270(6.9%)例主要结局和心血管疾病发生,队列 2 中分别有 391(11.9%)和 270(6.9%)例主要结局和心血管疾病发生。队列 2(与队列 1 相比)在复合终点(HR 0.73,95%CI 0.62 至 0.86)和心血管疾病(HR 0.64,95%CI 0.52 至 0.79)方面显示出显著的风险降低,并且同样独立于五个风险的累积而显著降低。
队列 2 心血管疾病的显著降低独立于基线协变量,提示近期治疗进展带来的综合效应。